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Abstract
Diet impacts anxiety in two main ways. First anxiety can be caused by 
deficiencies in antioxidants, neurotransmitter precursors, amino acids, cations 
and vitamins and other cofactors. Second, anxiety can be reduced by anxiolytic 
nutraceuticals which are food molecules that bind to molecular targets of the 
amygdala and the hypothalamus-pituitary–adrenal axis (HPA-axis). Anxiety is a 
feeling of fear that arises from a perceived threat and can be a beneficial coping 
mechanism to threats and stressors. However excessive anxiety is a disorder that 
interferes with healthy responses to stressors. The amygdala is responsible for 
assigning value to a threat or stressor and triggering the HPA-axis to support the 
body wide system responses to the threat. The amygdala also communicates with 
the neuroplastic learning and memory centers of the hippocampus to fix or set 
a learned value to the threat. Interestingly, many anxiolytic nutraceuticals that 
show benefits in human clinical trials have neurotrophic activity and increase 
neuronal plasticity. Moreover, anxiolytic nutraceuticals either act like the 
neurotrophins, nerve growth factor (NGF), brain derived neurotrophic factor 
(BDNF and neurotrophin-3 (NT3) by either directly binding to or potentiating 
the tyrosine receptor kinase (TRK) family of receptors (TRKA, TRKB and TRKC) 
and activating the ERK1/2 signal transduction pathway associated with neurite 
outgrowth and neural plasticity. This chapter will explore the neuritogenic 
activity of clinically proven plant-based anxiolytic nutraceuticals and examine 
the commonality of TRKA-C receptors and the ERK1/2 signaling pathway in the 
pharmacological and nutraceutical treatment of anxiety disorders.
Keywords: Anxiety, Anxiolytic, Nutraceutical, Cannabidiol, Neurotrophin,  
Neurite Outgrowth, NGF, BDNF, NT3, TRKA, TRKB, TRKC, ERK1/2
1. Introduction
In humans, the appropriate and measured behavioral responses to environmental 
cues are under control of the limbic nervous system which is composed primar-
ily of the amygdala, hippocampus, thalamus, and hypothalamus [1]. In order for 
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sensory inputs to the cerebral cortex to result in the appropriate responses in the 
body, sensory inputs relay from the cerebrum, to the limbic system and then from 
the limbic system to the body either through the brainstem or through the pituitary 
gland. It is when relaying sensory inputs from the cerebral cortex to the body that 
the limbic system also assigns emotional value to sensory input and sets or fixes that 
value by learning and remembering the rewards and punishments associated with 
specific environmental cues. The amygdala is known for assigning a scaled value to 
negative threats and stressors which the amygdala then communicates to learning 
and memory centers in the hippocampus so that human behavioral responses to 
negative cues can be consistent and appropriate. The amygdala also stimulates the 
hypothalamus to secrete corticotrophin-releasing hormone (CRH) which in turn 
stimulates the pituitary to release adrenocorticotropin hormone (ACTH), which in 
turn stimulates the adrenal cortex to secrete glucocorticoids including primarily, cor-
tisol in what is known as the HPA-axis [2–4]. The hypothalamus can also send signals 
through the brainstem and activate the adrenal medulla to secrete epinephrine and 
norepinephrine. Cortisol, epinephrine and norepinephrine are hormones that can 
signal body wide changes in metabolic rates, breathing, heart rate, blood pressure 
and a variety of other appropriate body responses to the presence of an environmen-
tal threat or stressor [2, 3]. Anxiety is the feeling of fear or worry that arises from 
the neurochemistry of the amygdala in response to negative environmental cues and 
the activation of the HPA-axis and the overall preparation of the body to meet the 
challenges of a threat or stressor and while anxiety is a negative feeling, when it is in 
proportion to the actual threat a stressor presents, anxiety can be a normal and even 
healthy part of an adequate response to the stressor [5–7]. However, excessive and 
prolonged anxiety that is unwarranted by the environmental cue and exaggerated in 
proportion to the actual threat level leads to inappropriate and prolonged activation 
of the HPA-axis and cortisol release which is associated with inflammatory damage 
and other pathophysiologies that further stresses the human body system [2–4]. In 
these cases anxiety interferes with normal and health everyday life and is considered 
an anxiety disorder [8, 9].
People suffer from five different types of anxiety disorders; generalized anxiety 
disorder (GAD, obsessive compulsive disorder (OCD), panic disorder (PD), social 
anxiety disorder (SAD), and posttraumatic stress disorder (PTSD) [8, 9]. Each of 
these anxiety disorders can be described by the level of synaptic neurotransmitters 
and cell surface neurotransmitter receptors in the amygdala [1, 8, 9]. For example, 
GAD is associated with decreased activity of the inhibitory neurotransmitter, 
GABA. GABA acts on GABAA receptors on neurons within the amygdala to inhibit 
signals and help to assign lower threat values to certain stressor. Down regulation 
of the GABAA receptor and the subsequent reduction of GABA signaling in the 
amygdala leads GAD through elevated valuation of threats [10]. Similarly, PD is also 
associated with decreased GABAnergic transmission and subsequent over stimula-
tion of neural pathways, however in PD the decrease GABAnergic signaling may be 
due to reduced level of the GABA neurotransmitter itself and not due to decreased 
GABAA receptors as seen in GAD [9, 11, 12]. While GABAnergic pathways in the 
amygdala are inhibitory and stress reducing, glutamate, the major stimulatory 
neurotransmitter, when over active in the amygdala enhances stress and can lead to 
OCD. Pharmacological enhancement of glutaminergic signals in the frontolimbic 
regions of the brain enhance anxiety and imaging studies have shown increased 
glutaminergic activity in various structures of the limbic system in the brain 
[13–15]. PTSD and SAD also appear involve increased glutaminergic activity in the 
amygdala [9, 16]. GABA and glutamate influence the feeling of anxiety be reduc-
ing and enhancing the perceived threats, while the neurotransmitters, serotonin 
and dopamine are associated with the reward and pleasure pathways of the limbic 
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system and can influence the overall perception of environmental stressors gener-
ally reducing anxiety. For example, SAD is associated with both decreased activity 
at serotonin receptors and also decreased dopamine levels in limbic neurocircuitry 
[9, 16, 17]. Taken together, anxiety disorders involve irregularities in the levels of 
neurotransmitters and neurotransmitter receptors in the neurocircuitry of the 
limbic system. The inappropriate levels of neurotransmitters and their receptors 
can lead to hyper activity in regions of the limbic system such as the amygdale 
and lead to incorrect and unhealthy assessment of the risks and threats associated 
with stressors or lack of stressors and lead to anxiety and fear potentially even 
in the absence of threat. Activation of the HPA-axis can contribute to both the 
clinical signs and symptoms of anxiety and also lead to chronic glucocorticoid 
induced pathologies which serve and further internal stressors and add to anxiety. 
Treatments for anxiety disorders have therefore focused on developing drugs that 
correct and manage the levels of neurotransmitters and neurotransmitters receptors 
and signaling in the limbic system pathways and particularly in the amygdala.
GABAnergic benzodiazepines are the favored class of anxiolytic medications 
[10, 11, 18]. The diazepine ring is a seven membered ring structure containing 
two nitrogens and this diazepine ring and when fuses with a benzene ring forms 
a benzodiazepine that can bind to GABAA receptors on neurons in the brain [18]. 
Benzodiazepines are favored due to their lesser side-effects compared to other 
anxiolytic drugs, although side effects are still concerns [18]. The mechanism of 
benzodiazepine signaling is binding to either GABAA or GABAB receptors and 
allowing either chlorine ions into the cell at the synapse or stimulating the release 
of potassium from the cell into the synapse respectively [10, 11, 18]. In the cells 
of the amygdala, the chlorine influx inhibits the signaling of the pathway and 
diminishes the level of potential threat assigned to a sensory input or any external 
or internal stressor. People with GAD and PD express low levels of GABAA and 
produce less GABA respectively thereby limiting the patient’s ability diminish the 
signals from stressors is associate with a heightened sense of fear and worry. By 
being GABAnergic the benzodiazepines help to restore or boost the GABAnergic 
pathway and the therefore the reduction of anxiety. Alternatively to drugs that 
act in a GABAnergic fashion, serotonin and dopamine uptake inhibitors, often 
used for depression, reduce anxiety and fear by increasing levels of these “feel 
good” neurotransmitters in the limbic neurocircuitry. Low synaptic serotonin and 
dopamine in the amygdale and nucleus accumbens is associated SAD. Serotonin 
uptake inhibitors (SSRIs) and noradrenalin and dopamine reuptake inhibitors 
(NDRIs) increased the level of serotonin and dopamine in the synapse and have 
been used to treat depression and also provide relief from anxiety and anxiety 
disorders. [18–22].
In addition to the development of new drugs that interact with the amygdala 
and HPA-axis, anxiety can also be addressed by diet. The diet can be associated 
with anxiety in two main ways. First, if a diet is deficient in nutrients such as 
selenium, lysine, magnesium and inositol, changes in food consumptions or dietary 
supplementation can replace the deficient nutrient, balance the diet and alleviate 
anxiety [23]. Further, dietary deficiencies in antioxidants can lead to the buildup 
of reactive oxygen species (ROSs) that form as a part of normal metabolism and 
are reactive chemicals that can bind to DNA, lipids and proteins leading to DNA 
and membrane damage and cellular toxicity. This cellular damage serves as a 
stress signal and is associated with anxiety [24, 25]. Therefore, increasing dietary 
antioxidant intake can help with anxiety. Second, food nutrients can directly 
affect the neurochemistry of the limbic system by either directly boosting GABA 
or Serotonin levels or by binding to neurotransmitter receptors. For example, 
GABA is an amino acid is available directly in the diet. Further the amino acid, 
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5-hydroxytryptophan is a serotonin precursor and is a popular dietary supplement 
taken to easy feelings of anxiety and stress. While it is not clear if increasing oral 
consumption of GABA and 5-hydroxytrptophan can increase brain GABA and 
serotonin levels, clinical studies have shown and relaxing effect of GABA and 
5-HTP supplementation [23]. The neurochemistry of the brain can also be altered 
by food chemicals eaten from bacteria, fungi and plants that have nutraceutical 
effects by acting in a drug-like fashion as cell signaling molecules and alerting 
cellular behavior. In this chapter we focus on food nutraceuticals that are anxiolytic 
in humans and alter the neurochemistry and the amygdala and other limbic 
structures in the brain. Of particular interest are anxiolytic phytochemicals that in 
addition to changing the brain neurotransmitter physiology also stimulate neuronal 
plasticity through the activation and or potentiating of neurotrophin receptors and 
signal transduction pathways.
Recent studies have revealed that numerous anxiolytic substances, including 
endogenous neurotransmitters, anxiolytic drugs, and nutraceuticals, are also 
neurotrophic in that they also activate the brain derived neurotrophic factor 
(BDNF) pathway, the neurotrophin-3 (NT-3) pathways and the nerve growth 
factor (NGF) pathway by binding to or potentiating the TRKA – C neurotrophin 
receptors and directly activating the ERK1/2 signaling pathway leading to 
neuroplasticity [26–37]. This is important because neurotrophins can regulate 
neuroplasticity not only during development but also during learning and the 
establishment of memories [35–37]. Neurotrophins are small soluble signaling 
molecules that can diffuse between cells to play a role in cell–cell communication 
[35–37]. These neurotrophic factors include BDNF, NGF and NT3 bind to cell 
surface molecules on neuronal cells known as the tropomyosin receptor kinases 
(TRK) A – C respectively [35–37]. Neurotrophin signaling is associated with 
neuritogenesis or new neurite formation in neuronal cells. The changes in cell 
shape associated with the establishment of new neurites and therefore potentially 
new connections is known as neuroplasticity [35–37]. Recent attention has been 
brought to the idea that in so far as anxiety is related to the memories of trauma and 
the establishment of a learned threat level in the perception of stressors through 
neuroplasticity, perhaps anxiolytic phytochemicals with neurotrophic activity can 
be used to reduce anxiety not only through changes neurotransmitter activity, but 
also by providing the plasticity required to relearn and reduce the emotional value 
ascribed to a stressor thereby also facilitating the reduction in anxiety [26–34]. 
Therefore anxiolytic phytochemical neurotrophins are important because they 
offer a new area of research into not simply adjusting neurotransmitter activity, 
but to the development of natural treatments and drugs that can actually reverse 
the neurocircuitry associated with anxiety through neuroplasticity and relearning. 
It is important to note however, not all anxiolytic phytochemicals are capable of 
stimulating neuroplasticity. The following section of this chapter will present 
all nutraceutical phytochemicals that are anxiolytic in human clinical trials that 
also show potential for stimulating neuroplasticity either by directly stimulating 
neuritogenesis or neurite outgrowth neuronal cells or by binding to the TRKA-C 
neurotrophin receptors and or by the activation of the neurotrophin ERK1/2 signal 
transduction pathway and others associated with neurite formation.
2.  Clinically relevant anxiolytic phytochemicals with neurotrophic 
activity
In this chapter we present only plants and plant extracts that contain phyto-
chemicals that are both shown to be anxiolytic in human clinical trials and also 
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possess neuroplastic properties (Table 1). The specific anxiolytic nutraceutical or 
phytochemical in the plant is in most cases not known, in part because neuroactive 
plants usually contain many nervine agents. Often however there is a suspected 
phytochemical or group of phytochemicals thought to be responsible for the 
anxiolytic activity. In some cases the anxiolytic nutraceutical in the plant extract is 
the same phytochemical that has the neurotrophic activity, while in other cases it 
may be a different phytochemical in the plant extract. Anxiolytic drugs adjust neu-
rotransmitter and neurotransmitter receptors levels which leads to increased drug 
insensitivity, extreme withdrawal effects and a return to imbalance neurotrans-
mitter and neurotransmitter receptor levels when and if the drug is removed. In 
addition to altering neurotransmitter and receptor levels neuroplastic anxiolytics 
also stimulate the new neurite connections associated with learning and remem-
bering appropriate responses to stressors. If a new response to a threat is learned, 
then treatment of the anxiety disorder may not require dosage increases and the 
newly learned healthy perceptions of threats could remain with the patient even if 
the drug or treatment is removed or reduced. This would represent a tremendous 
advancement in the treatment of anxiety disorders. Table 1 is a list of the fourteen 
clinically supported anxiolytic plants that also have neuroplastic properties.
2.1 Theanine
Theanine is an amino acid that when taken as a green tea extract or in a purified 
form is able to reduce anxiety in clinical trials [38–40]. When administered in a 
double blind placebo controlled study, theanine was shown to reduce stress-induced 
salivary cortisol levels [39]. However in other studies, while theanine did improve 
the sleep in people with GAD, theanine did not reduced anxiety scores on the 
HAMA scale [41]. Both animal and in vitro studies have suggested that theanine 
supplementation increases brain serotonin, dopamine and GABA levels and that the 
cellular target for theanine includes glutamate receptors to which theanine binds 
and antagonizes the stimulating action of glutamate on neurons [42–44]. With 
regard to neuroplasticity, theanine facilitates neuritogenesis in the developing rat 
hippocampus and enhances object learning memory [45]. Further, dietary theanine 
increases nerve growth factor (NGF) levels in the developing rat brain [46]. 
Theanine is not the only green tea molecule that can affect neurotrophin activity. 
The catechins from green tea have been show to potentiate BDNF binding to TRKB 
receptors in PC12 cells and enhance neurite outgrowth [47], and potentiate NGF 
signaling through TRKA receptors and enhance neurite outgrowth also in PC12 cells 
[48]. Further, the green tea catechin, green tea polyphenol (−)-epigallocatechin-3-
gallate (EGCG) also stimulates neurite outgrowth in cultured PC12 neurons [49].
2.2 Chamomile
In clinical trials, chamomile has been shown to decrease the symptoms of 
general anxiety disorder [50, 51], in part by exerting an effect on diurnal cortisol 
changes [52]. While not yet known, apigenin is a plant flavone component of 
chamomile which is thought to contribute to the anxiolytic effects of chamomile 
[53]. Interestingly, apigenin increases neurite formation in murine N2a cells [54] 
and reverses PTZ induced behavioral impairments in mice by increasing hip-
pocampal levels of brain derived neurotrophic factor (BDNF) [55]. Apigenin also 
has been shown to increase hippocampal BDNF levels in a chronic corticosteroid 
treatment model of depression in mice [56]. Apigenin also activates the ERK1/2 
pathway in PC12 cells and while not sufficient to stimulate differentiation in 







Green Tea/theanine Increases brain BDNF 
levels
hippocampal cells [45, 46]
Increases brain NGF 
synthesis
Neural stem cells
Potentiates NGF at 
TRKA





Lavender/N.D. Increases brain NGFR neuronal cells [67, 68]
Ashwagandha/N.D. Increases brain GDNF hippocampal cells [75]
Passion Flower/
apigenin
Potentiates NGF PC12 cells [80]






PC12 cells [102, 103]
NGF potentiation
Citrus/limolene ERK1/2 activation PC12 cells [110–113]













Increases NT-3, BDNF stem cells [130, 131]
and NGF; ERK1/2 
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N.D. hippocampal cells [141, 142]
dorsal root ganglia
All plants listed above have been shown to be anxiolytic in human clinical trials. In some cases the anxiolytic 
molecules and neurotrophic activities have not been determined (N.D.). Neurotrophic activities are those associated 
with activating neurotrophin signaling pathways by increasing levels of neurotrophin (NGF, BDNF, NT3, GDBF) 
synthesis, or by directly binding to neurotrophin receptors (TRKA, TRKB, TRKC and NGFR) or by activating the 
ERK1/2 signaling pathway. Another neurotrophic activity is the induction of neurite outgrowth or neuritogenesis 
in neuronal cell cultures and in. In these cases the names of the cells or tissues showing a neuroplastic response is 
provided.
Table 1. 
The neurotrophic activities of anxiolytic plant extracts and phytochemical nutraceuticals.
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expressing PC12 cells [58] again linking dietary phytochemicals that are anxio-
lytic to neural plasticity.
2.3 Lavender
Lavender oil also has anxiolytic effects in clinical trials in which it can both 
reduce anxiety associated with stressful event such as surgeries and recovery and 
also reducing anxiety in anxiety disorders [49–63]. Targets for lavender oil include 
the 5-HT1A serotonin receptor, the NMDA receptor and the serotonin transporter 
(SERT) [64, 65]. Linalool, a lavender oil terpene in specific can bind to SERT [64]. 
In a clinical trial where subjects were subjected to stress, linalool helped to reduce 
stress as measured by salivary cortisol levels, blood pressure and heart rate [66]. 
While linalool may be responsible for much of the anxiolytic effects of lavender oil, 
linalool has not been shown to have neurotrophic activity, however, lavender oil 
has be shown to increase neurite outgrowth and synapse formation in neuronal cell 
cultures [67] and increase both BDNF and nerve growth factor receptor (NGFR) 
levels in mouse brain [68]. Activation of NGFR is associated with enhanced TRKA 
receptor activity in neurons which triggers neurite outgrowth in response to NGF 
signaling [69, 70].
2.4 Ashwagandha
Ashwagandha is a plant used in Ayeurvic medicine from which the roots and 
berries have been used as adaptagens and also to relieve stress. In double blind 
placebo controlled clinical trials Ashwagandha supplementation has been shown 
to reduce anxiety based reducing both scores on the Hamiltion-Anxiety (HAMA) 
scale and morning salivary cortisol [71] and reduce anxiety in a variety of other 
contexts including schizophrenia and sleep disorders [71–73]. With regard to 
brain neurochemistry, Ashwagandha does not appear to affect sertotonergic, 
GABAnergic, or glutaminergic pathways but instead increases cholinergic signaling 
in the cortical and basal forebrain [74]. While the specific bioactive molecule(s) in 
Ashwagandha that are anxiolytic have not been specifically identified, sominone, an 
aglycone derivative of Withanoside IV when injected into mice stimulated neurite 
outgrowth in the hippocampus and increased production of the neurotrophin, Glial 
Derived neurotrophic Factor (GDNF) [75]. Further injection of sominone into mice 
enhances spatial memory, again suggesting that anxioloytic phytochemicals that are 
neurotrophic may ease anxiety by providing signals to enhance neural plasticity and 
learning [75].
2.5 Passion flower
Passion flower also shows anxiolytic properties in clinical trials that are as 
effective as midazolam and oxezepam [76, 77] and can reduce anxiety associated 
with ambulatory surgery and dental extraction [77–79]. The anxiolytic molecule 
from passion flower has not been identified and the effects of passion flower on 
brain neurochemistry is not well studied. It is interesting to note however that 
C-dideoxyhexosyl flavones from passion flower have been shown to enhance NGF-
induced neurite outgrowth in PC12 cells [80].
2.6 Cannabidiol
Cannabidiol (CBD) is anxiolytic and has been shown in clinical trials to 
reduce social stress [81] and reduces anxiety in social phobia patients [82]. CBD 
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also reduces anxiety associated with drug-craving during recovery from heroin 
addiction [83]. With regard to brain neurochemistry in clinical trials, CBD 
reduction in SAD was associated with increased blood flow in the limbic and 
paralimbic brain areas [84]. CBD is anxiolytic through direct binding of the GABAA 
receptor and activating the GABAnergic pathway [85–87]. CBD also bind to the 
NGF receptor, TRKA which signals the ERK1/2 signal transduction pathway and 
stimulates neurite outgrowth in PC12 cells [88]. Indeed the mechanism of action 
of CBD is recognized to help with the neuronal plasticity through autophagy and 
neuritogenesis and may help not only with anxiety, but also with other psychiatric 
disorders [88, 89]. Due to the lipophilicity of CBD, there is interest in developing 
emulsification techniques to increase CBD bioavailability when taken in the diet. 
For example, nanoemulsification [90] and lipid extractions [91] and lipid-vehicles 
[92] and piperine nanoliposhperes of CBD [93, 94] have been investigated for better 
oral absorption and better bioavailability for cellular targeting. Nanoemulsified, 
versus lipid emulsified CBD were tested for their ability to stimulate neurite 
outgrowth in PC12 cells (Figure 1). Continuous lipid extracted CBD shows 
greater bioavailability and activity compared to nanoemulsification and piperine 
nanoliposheperes (Figure 1).
2.7 Valerian root
The anxiolytic activity seen in patients supplementing with Valerian root extract 
[95], is known to be due to the sesquiterpene, valerenic acid [96]. While there is 
evidence to suggest that valerenic acid activates the GABAnergic pathway [97, 98], 
Figure 1. 
The effects of CBD on PC12 cell neurite outgrowth. PC12 cells were seeded on tissue culture plastic in a serum 
free defined medium and the percentage of cells that formed neurites were counted by visual inspection over 
a five day period. Cells were either untreated (blank) or treated with 100 ng/ml nerve growth factor (NGF) 
or with 10 uM of five different CBD formulations (CBD1-CBD5). CBD designations are as follows: CBD 
isolated by continuous lipid extraction, (CBD1), CBD1 + vitamin C (CBD2), nano-emulsion CBD (CBD3), 
liposomal-emulsion CBD (CBD 4) and piperine nanoliposhpere preparation CBD (CBD5). CBD1 and CBD2 
were statistically significantly more neuritogenic at 95% confidence (*) on days three and five (p < 0.05, t-test) 
compared to any of the other CBD formulations.
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growing evidence suggests that valerenic acid mediates anxiolytic effects also by 
both antagonizing glutaminegric pathways [99, 100] and agonizing the serotonin 
receptor [101]. Valerenic acid also activates secretion of BDNF in cultured SH-SY5Y 
neurons [102]. Interestingly, germacrane, another sesquiterpene extracted from 
Valerian root, while not associated with an anxiolytic activity, has been shown to 
potentiate NGF and TRKA signaling and neurite outgrowth in PC12 cells [103]. An 
aqueous extract of valerian root enhances NGF-mediated neurite outgrowth and 
neuroplasticity but unlike CBD, the valerian extract is not neurotrophic in PC12 
cells in the absence of NGF stimulation (Figure 2).
2.8 Citrus
Citrus plant extracts, including those from lemon, bitter orange, and bergamot 
relieve anxiety in clinical trials. For example, lemon inhalation reduced anxiety in 
myocardial infarction patients [104] and bergamot aromatherapy reduced preopera-
tive anxiety [105] and bitter orange aroma therapy relieves anxiety in patients with 
acute coronary syndrome [106] and chronic myeloid leukemia [107] and preopera-
tive anxiety [108]. Bitter orange extract contains primarily limolene and b-myrcrene, 
appear to act on the 5-HT serotonergic pathway [109]. When tested in PC12 cells, 
citrus phytochemicals such as nobilitin, gardenin A and auraptene all stimulate 
neurite outgrowth [110–112] and 5-Hydroxy-3,6,7,8,3′,4′-hexamethoxyflavone from 
sweet orange peel stimulates neurite outgrowth in and NGF-like fashion activating 
the ERK1/2 signaling pathway suggesting binding to TRKA [113].
Figure 2. 
The effect of valerian root extract and valerenic acid on neurite outgrowth in PC12 cell cultures. PC12 cells 
were seeded in serum free defined medium and treated as indicated with 10 ng/ml NGF, 100 μM valerenic acid 
and 50 mg/ml of 4:1 aqueous valerian root extract. The percentage of cells that formed neurites was counted 
by visual inspection over a five day period. More neurites were seen in PC12 cells treated with the valerian 
root extract and NGF when compared to NGF alone and these differences were statistically significantly at 
95% confidence (*) on days one, three and five (p < 0.05, t-test). These data suggest valerian root extract 




Saffron has been shown to be anxiolytic in two double blind placebo controlled 
clinical trials. [114, 115] and while the active anxiolytic molecule in Saffron has not 
been identified, crocin, a carotinoid in Saffron, has been shown to increase BDNF 
and GDNF expression in neuronal stem cells [116] and also increase hippocampal 
BDNF and protect the murine brain from methamphetamine toxicity [117].
2.10 Bacopa monnieri
In double blind placebo controlled trials, Bacopa monnieri, an adaptagen of 
Ayruvic medical tradition, has been show to enhance cognition and reduce anxiety 
[118, 119]. This anxiolytic adaptagen has been shown to increase nerve NGF 
expression in rats [120]. A saponin isolated from Bacopa monnieri, Bacopacide I, has 
been shown to have antidepressant activity in mice by modulating the HPA axis and 
enhancing BDNF mRNA expression in the hippocampus and prefrontal cortex of 
mice [121].
2.11 Skullcap
Skuttleria is a genus of plants known as the skullcaps that include scutellaria 
Radix and Scutellaria lateriflora (American skullcap). American skullcap has been 
shown to be anxiolytic in humans as shown by a reduction in anxiety in healthy 
volunteers using the Beck Anxiety Inventory (BAI) [122, 123]. The Skullcap flavone, 
baicalin which is found in american sckullcap and other members of the skuttleria 
genus has been shown to be anxiolytic by binding to GABAA receptors in mice [124, 
125]. Interestingly biacalin increases hippocampal BDNF expression and in doing 
so protects the hippocampus from corticosterone induced depression in mice [126]. 
In addition biacalin stimulates neurite outgrowth in C17.2 neuronal stem cells by 
signaling through the ERK1/2 pathways, the known signal transduction triggered 
by NGF binding to TRKA [127].
2.12 Rhodeola Rosea
Rhodeola Rosea has been shown to reduce GAD in small pilot and self reporting 
clinical trials [128, 129]. While the effects of Rhodeola on brain neurochemistry 
has not been well studied, salidroside, a glycoside from Rhodiola has been shown to 
increase stem cells expression of neurotrophin-3 (NT-3), BDNF, NGF mRNA and 
induce differentiation into neurons [130] and also activates the ERK1/2 pathway in 
NGF treated PC12 cells [131].
2.13 Hops
One study shows Hops to be anxiolytic in clinical trials [132]. Prenylflavinoids 
from extracted from Hops can both bind to the benzodiazepine binding site on 
GABAA receptors [133, 134] and stimulate neurite outgrowth through TRKA a 
signaling in PC12 cells and cultures of dorsal root ganglia neurons [135, 136].
2.14 Nigella sativa
One clinical study shows that Nigella sativa seeds are anxiolytic in clinical 
trials [137]. Oral administration of Nigella extracts increase brain serotonin level 
in rats [138, 139] and thymoquinone, a terpine from Nigella is anxiolytic through 
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a GABAnergic pathway when orally administered to mice [140]. Thymoquinone 
promotes neurite outgrowth in rat hippocampal neurons and dorsal root ganglion 
neurons [141, 142].
3. Conclusion
Phytochemical nutrients that are used to reduce anxiety may have this affect in 
part by stimulating neuroplasticity and altering the brain neurocircuitry associated 
with learned responses to stressors and threats. Fourteen of the roughly forty-five 
plant and plant extracts proven to reduce anxiety in humans in clinical trials are also 
able to act like neurotrophins; endogenous molecules that stimulate neuroplasticity 
in the human brain. Anxiolytic drugs are harsh and symptoms return when the 
drug is removed because the neurotransmitter chemistry returns to an imbalance. 
Neuroplasticity offers an opportunity to use food phytochemicals along with drugs 
or in their place to learn to establish more appropriate responses to perceived threats 
by reworking neural connections. These new neural connections may not be lost 
even when the anxiolytic treatment is removed. Using neuroplastic drugs and foods 
to not only alter brain chemistry, but also the circuitry, would be a tremendous 
advancement in the treatment of anxiety.
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